Gedeon Richter Polska Sp. z o.o. is implementing a project entitled “Development of a manufacturing technology for a generic medicinal product used in the treatment of hyperuricaemia, based on an active substance in a new polymorphic crystalline form” under  action POIR.01.02.00: Sectoral R&D Programmes within the Smart Growth Operational Programme 2014–2020. The funding agreement was concluded with the National Centre for Research and Development. The objective of this project is to develop, within the planned R&D work, a manufacturing technology for a generic medicinal product used in the treatment of hyperuricaemia and gout, based on an active substance in a new polymorphic crystalline form. The Company’s generic medicinal product will possess distinctive characteristics of key importance from the perspective of end-user markets, including:

• High therapeutic efficacy,
• Enhanced safety of use,
• Stability confirmed across a range of environmental conditions,
• Competitive pricing.

Total project value: PLN 2,992,013.
Co-financing from the European Regional Development Fund: PLN 1,196,805.

This goal will be achieved through the implementation of two development stages covering process development and validation for the medicinal product, as well as pharmaceutical and clinical bioequivalence studies. The final outcome will demonstrate that the product manufactured by the Company has equivalent or similar bioavailability to the reference product, while exhibiting improved safety due to the polymorphic form applied.

Gedeon Richter Polska Sp. z o.o. delivered a project entitled “Expansion of the Gedeon Richter R&D laboratory through the establishment of a unit specialising in innovative methods for producing active substances in nanoparticle form” under action 2.1 Support for Investments in Enterprise R&D Infrastructure of the Smart Growth Operational Programme 2014-2020.

Total project value: PLN 6,715,712.73.

Co-financing from the European Regional Development Fund:  PLN 857,538.19.

The project involved the acquisition of fixed assets in the form of specialised research equipment and intangible assets to support the development of the Gedeon Richter Polska R&D Centre. The equipment is located at the Company’s headquarters in Grodzisk Mazowiecki. As a result of this project, the material conditions needed to conduct the scheduled research activities were established.

Gedeon Richter Polska Sp. z o.o. is implementing a project entitled „Development of innovative methods for obtaining active substances in nanoparticle form for use in the manufacturing technology of BCS IV class products”.

The project is co-financed by the European Union under the Smart Growth Operational Programme 2014–2020. Priority axis: Support for R&D activities by enterprises.
Action: R&D projects by enterprises. Sub-action: Industrial research and development work conducted by enterprises.

Total project value: PLN 5,261,185.87.

EU co-financing:   PLN 2,596,206.91.

Under this project, research will focus on developing innovative methods to obtain active substances in nanoparticle form for use in manufacturing BCS IV class medicinal products – compounds with low solubility and low absorbability. Additionally, analytical methods will be developed to confirm product quality in accordance with European Union guidelines.
The research programme will be carried out in collaboration with Polish scientific institutions and enterprises, including partners from the SME sector. The results will be implemented in the Company’s production facility in Poland.